sellWeak
Aguilar-Cordova Estuardo sold $244k of CADL
owner at Candel Therapeutics, Inc.. 40,412 shares at an average of $6.03, traded Oct 11, 2024, filed Oct 15, 2024.
Warning score
25Value
$244k
40,412 shares
Holdings after
919,461
-4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -27.7%, 3m +31.8%, 6m -16.8%.
Price, last year
Rows in this filing
Every transaction in Form 4 0001873919-24-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 11, 2024 | SOpen-market sale CADL | -15,000 | $6.05 | $91k | 944,873 | Oct 15, 2024 |
| Oct 14, 2024 | SOpen-market sale CADL | -15,000 | $6.02 | $90k | 929,873 | Oct 15, 2024 |
| Oct 15, 2024 | SOpen-market sale CADL | -10,412 | $6.03 | $63k | 919,461 | Oct 15, 2024 |
Related signals
Other insiders at Candel Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 14Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Barone Francesca Chief Scientific Officer | $282k | 32,146 | |
| 38Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Tak Paul Peter Chief Executive Officer | $230k | 26,172 | |
| 21Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Nichols William Garrett Chief Medical Officer | $397k | 45,316 | |
| 21Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Schoch Charles See Remarks | $44k | 5,000 | |
| 19Weak | sell 510b5-1 | CADL Candel Therapeutics, Inc. | Tyagarajan Seshu Chief Technology Officer | $276k | 31,278 | |
| 45Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Barone Francesca Chief Scientific Officer | $98k | 13,534 | |
| 43Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Nichols William Garrett Chief Medical Officer | $75k | 10,428 | |
| 51Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Tak Paul Peter Chief Executive Officer | $157k | 21,704 | |
| 43Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Schoch Charles See Remarks | $69k | 9,511 | |
| 45Moderate | sell 5 | CADL Candel Therapeutics, Inc. | Tyagarajan Seshu Chief Technology Officer | $103k | 14,322 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.